To the Editor,
We had initially indicated that there is a local hematopoietic bone marrow (BM) renin-angiotensin system (RAS), active in the physiological and pathological hematopoiesis (reviewed by Haznedaroglu and Beyazit [1]). Turkish Journal of Hematology has already published two critical research papers on the impact of the local BM RAS on the pathobiological course of neoplastic hematological disorders [2,3].
Angiotensin-converting enzyme 2 (ACE2), an essential component of the RAS, is also the critical receptor of the SARS-CoV-2 virus, which is the responsible agent of the currently ongoing pandemic COVID-19. COVID-19 affects hematopoiesis [4] besides its well-known pulmonary involvement like other previous SARS viral infections [5]. The receptor binding domain for the spike protein of the SARS-CoV-2/ACE2 seems to be similar to that of the coronavirus strain involved in the 2002-2003 SARS outbreak [6].
Here we would like to point out that the hematopoietic effects of COVID-19/SARS viral infections including lymphopenia, leukoerythroblastosis, and macrophage activation syndrome may be linked to the viral effect on the local RAS [1] in the BM microenvironment. Leukoerythroblastic reactions associated with normocytic anemia, occasional nucleated red blood cells, mild anisocytosis, and rare dacrocytes were observed during the clinical course of COVID-19 infections [4]. Lymphopenia is a critical prognostic biomarker of the severity and hospitalization of the patients with COVID-19 [7]. The imbalance between the ACE/angiotensin II/AT1R pathway and ACE2/angiotensin (1-7)/Mas receptor pathway in the RAS leads to the multi-system inflammation [8]. Likewise, macrophage activation syndrome is an essential integral part of the COVID-19 pathophysiology [9]. Similarly, enhanced expression of ACE in the lymphoma-associated macrophages in the lymph nodes in Hodgkin’s disease was previously demonstrated with regard to the local RAS [10].
The interrelationship between COVID-19, RAS, and hematopoiesis is not just an academic concern since the future modulation of the local RAS may be performed with directed RAS modulators, such as soluble ACE2, angiotensin (1-7), TXA127, and MAS receptor agonists. Topical soluble ACE2 has already been suggested as a ‘drug-of-hope’ for the pharmacobiological management of COVID-19 based on future controlled clinical trials [11].
Footnotes
Authorship Contributions
Data Collection or Processing: İ.C.H.; Analysis or Interpretation: İ.C.H.; Writing: R.Ç.
Conflict of interest statement: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
Financial Disclosure: The authors declared that this study received no financial support.
References
- 1.Haznedaroglu IC, Beyazit Y. Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis. Clin Sci (Lond) 2013;124:307–323. doi: 10.1042/CS20120300. [DOI] [PubMed] [Google Scholar]
- 2.Saka B, Sayitoğlu M, İstemihan Z, Karan MA, Erten N, Doğan Ö, Özbek U, Genç S, Taşçıoğlu C, Kalayoğlu-Beşışık S. The role of the local bone marrow renin-angiotensin system in multiple myeloma. Turk J Hematol. 2019;36:178–185. doi: 10.4274/tjh.galenos.2019.2018.0420. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Uz B, Tatonyan SÇ, Sayitoğlu M, Erbilgin Y, Hatırnaz O, Aksu S, Büyükaşık Y, Sayınalp N, Göker H, Ozcebe Oİ, Ozbek U, Haznedaroğlu İC. Local renin-angiotensin system in normal hematopoietic and multiple myeloma-related progenitor cells. Turk J Hematol. 2014;31:136–142. doi: 10.4274/tjh.2013.0011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Mitra A, Dwyre DM, Schivo M, Thompson GR 3rd, Cohen SH, Ku N, Graff JP. Leukoerythroblastic reaction in a patient with COVID-19 infection. Am J Hematol. 2020;95:999–1000. doi: 10.1002/ajh.25793. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Yang M, Li CK, Li K, Hon KL, Ng MH, Chan PK, Fok TF. Hematological findings in SARS patients and possible mechanisms (review) Int J Mol Med. 2004;14:311–315. [PubMed] [Google Scholar]
- 6.Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:1–3. doi: 10.1038/s41392-020-0148-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Sun M, Yang J, Sun Y, Su G. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E014–E. doi: 10.3760/cma.j.issn.1001-0939.2020.0014. [DOI] [PubMed] [Google Scholar]
- 9.Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Koca E, Haznedaroglu IC, Uner A, Sayinalp N, Saglam AE, Goker H, Ozcebe OI. Angiotensin-converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin’s disease. J Natl Med Assoc. 2007;99:1243-4, 1246–7. [PMC free article] [PubMed] [Google Scholar]
- 11.Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–913.e7. doi: 10.1016/j.cell.2020.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]